About Victor Kouassi

This author has not yet filled in any details.
So far Victor Kouassi has created 105 blog entries.


Rapid diagnostic tests to support clinical trials of antibiotics
– by Gian Maria Rossolini

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Due to the antibiotic resistance crisis that has dramatically emerged at the beginning of the new century, the past decade has seen a notable resurgence of clinical trials involving antibiotics1,2. Indeed,


Rapid diagnostic tests to support clinical trials of antibiotics
– by Gian Maria Rossolini2021-06-03T09:18:05+00:00


Will new antibiotic classes solve multidrug resistance?
– by Michael N. Dudley and Olga Lomovskaya

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” With the ever-increasing threat of antimicrobial resistance, there has been considerable discussion about approaches for new therapeutics. This is especially so for Gram-negative bacteria many of which the U.S. Center for


Will new antibiotic classes solve multidrug resistance?
– by Michael N. Dudley and Olga Lomovskaya2021-05-21T12:25:18+00:00


Introducing ProMED-AMR, the new ProMED network for antimicrobial resistance
– by Matthew E. Levison

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The Program for Monitoring Emerging Diseases or ProMED is an online global emerging infectious diseases and outbreak surveillance network1. It is the flagship program of the International Society for Infectious


Introducing ProMED-AMR, the new ProMED network for antimicrobial resistance
– by Matthew E. Levison2021-05-03T13:01:34+00:00


Causes of antibiotic shortages and the solutions to address them
– by Enrico Baraldi

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” There is no doubt that the world needs new antibiotics, especially truly innovative ones with new modes of actions to attack drug-resistant bacteria and counter the silent surge of antimicrobial


Causes of antibiotic shortages and the solutions to address them
– by Enrico Baraldi2021-03-24T15:24:33+00:00


Monitoring antimicrobial resistance in Ghana: a focus on the hospital environment
– by Abiola Isawumi and Lydia Mosi

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Ghana falls within the WHO hotspot for antimicrobial resistance (AMR) emergence in Sub-Saharan Africa1. Concerted efforts are therefore being made to contain the public health challenges posed by drug-resistant bacteria


Monitoring antimicrobial resistance in Ghana: a focus on the hospital environment
– by Abiola Isawumi and Lydia Mosi2021-05-21T09:20:38+00:00


Learning from IPC strategies for COVID-19 to mitigate AMR in rural Nigerian communities
– by Rachael Osagie

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The coronavirus disease (COVID-19) pandemic has revealed many areas of public health preparedness that are lacking, especially in lower- and middle-income countries. This reinforces the importance of preventative measures such


Learning from IPC strategies for COVID-19 to mitigate AMR in rural Nigerian communities
– by Rachael Osagie2021-01-22T10:47:45+00:00


The antibiotic R&D landscape in Japan
– by Norio Ohmagari

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Japan has contributed to the research and development of antimicrobial agents from early on and has developed many of them. The table presented below shows trends in the development of


The antibiotic R&D landscape in Japan
– by Norio Ohmagari2021-01-25T08:25:40+00:00


Tackling the drug-resistance pandemic – 2020 and beyond
– by Laura J.V. Piddock

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” It may seem strange when discussing tackling antibiotic resistance, but in this viewpoint, I will start by talking about SARS-CoV-2, the virus that is causing the COVID-19 pandemic. Other diseases


Tackling the drug-resistance pandemic – 2020 and beyond
– by Laura J.V. Piddock2021-01-25T08:26:44+00:00


Why are new antibacterials failing as commercial products?
– by Patricia A. Bradford

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The success of modern medicine relies upon access to effective antibacterial drugs. However, the continued threat of antibiotic resistance has resulted in an urgent need for new antibacterial treatments. In


Why are new antibacterials failing as commercial products?
– by Patricia A. Bradford2021-01-25T08:26:55+00:00


COVID-19: Coinfection, secondary bacterial infections and AMR in India
– by Venkatasubramanian Ramasubramanian

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The COVID-19 pandemic has brought in its wake dramatic and stressful changes in our lives. More significantly, we, as health care professionals, have had to adapt and evolve with the


COVID-19: Coinfection, secondary bacterial infections and AMR in India
– by Venkatasubramanian Ramasubramanian2021-01-25T08:27:13+00:00

Antibiotics and antimicrobial resistance

On Thursday 29th October at 4:00 PM to 6:00 PM CEST, the Interdisciplinary Course on Antibiotics and Resistance (ICARe) will be holding a special webinar in light of the 5th anniversary of the course. The two-hour event will be hosted by Patrice Courvalin and will feature presentations on antimicrobial research and development from Helen Boucher, Gerry Wright, Erin Duffy and John Rex. To find more information and to register click here.

Antibiotics and antimicrobial resistance2020-10-21T09:03:05+00:00


A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need
– by John Rex

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This commentary was originally published on 19 September 2020 on the AMR.Solutions website (amr.solutions) and adapted on 6 October 2020 as a Viewpoint for the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” In this Antimicrobial Viewpoint article, I explore the two types of clinical


A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need
– by John Rex2021-01-25T14:08:01+00:00

Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)

Speakers: James J. Collins, Termeer Professor of Medical Engineering & Science Professor, Broad Institute of MIT and Harvard (USA) Cesar de la Fuente, Presidential Assistant Professor, University of Pennsylvania (USA) Henriette Willems, Senior Research Associate, The ALBORADA Drug Discovery Institute, University of Cambridge (UK) Fredrik Svensson, Senior Research Associate, UCL Drug Discovery Institute (UK) Moderator: Laura Piddock, GARDP In this webinar, the speakers gave an overview of their work on the discovery of antibiotics through the use of artificial

Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)2021-01-14T15:19:00+00:00


Moving from paper to action – The status of National AMR Action Plans in African countries
– by Mirfin Mpundu

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The threat of antimicrobial resistance (AMR) could reverse gains made by modern medicine. In May 2015, the World Health Assembly endorsed the Global Action Plan (GAP) on AMR that called


Moving from paper to action – The status of National AMR Action Plans in African countries
– by Mirfin Mpundu2021-01-25T08:28:24+00:00

Building better breakpoints: data and methods needed to determine breakpoints for new agents

Speakers:  John Turnidge, Scientific Secretary, European Committee on Antimicrobial Susceptibility Testing and Clinical Professor, Adelaide Medical School, University of Adelaide (Australia)  Anouk Muller, Clinical Microbiologist, Haaglanden Medical Center, Netherlands and Erasmus University Medical Center, (Netherlands) Moderator: Gunnar Kahlmeter, EUCAST In this webinar, John Turnidge and Anouk Muller discussed how to determine breakpoints for new agents. The following topics were discussed: Preclinical data and methods: MIC distributions, ECOFFs, in vitro models, in vivo models, initial PK/PD parameters and targets Clinical

Building better breakpoints: data and methods needed to determine breakpoints for new agents2020-12-16T14:53:52+00:00

Building Medtech Companies: Learn how to attract investment to fund product development and scale your company

The Longitude Prize has launched a programme called Sprint which consists of expert support and technical workshops in the form of webinars that are available to all. The second of these webinars will take place on 30th September 2020 at 15:00 BST with the title of 'Building Medtech Companies: Learn how to attract investment to fund product development and scale your company'. To find more information and to register click here.

Building Medtech Companies: Learn how to attract investment to fund product development and scale your company2020-09-08T11:44:51+00:00

How do we simultaneously manage the acute COVID-19 pandemic and escalating antibiotic resistance?

The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) will hold the final webinar in their AMR Research in a post-pandemic world series on 18th September at 14:00 CEST. The title of the webinar will be 'How do we simultaneously manage the acute COVID-19 pandemic and escalating antibiotic resistance?' To find more information and to register click here.

How do we simultaneously manage the acute COVID-19 pandemic and escalating antibiotic resistance?2020-09-08T10:19:53+00:00

Antimicrobial Surveillance and consumption data – how, what and why to measure to provide meaningful data

On 17th September 2020 at 17:00 BST, the British Society for Antimicrobial Chemotherapy (BSAC) will hold a webinar with the title of "Antimicrobial Surveillance and consumption data – how, what and why to measure to provide meaningful data." The session will be chaired by Mark Gilchrist from Imperial College Healthcare NHS Trust, UK and Jacqueline Sneddon from Healthcare Improvement Scotland, UK. To find more information and to register click here.

Antimicrobial Surveillance and consumption data – how, what and why to measure to provide meaningful data2020-09-08T10:20:39+00:00


Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them
– by Jack Stone and Maria Laura Ciusa

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The number of drug-resistant bacterial infections is rising across the world and new treatments are urgently required1. One of the barriers to discovering new antibiotics is a lack of information


Knowledge sharing for antimicrobial research: AntibioticDB and SPARK and why researchers should use them
– by Jack Stone and Maria Laura Ciusa2021-01-25T08:29:15+00:00

Navigating MedTech Regulation Pathways in Developed and Emerging Markets

The Longitude Prize has launched a programme called Sprint which consists of expert support and technical workshops in the form of webinars that are available to all. The first webinar will take place on 7th August 2020 at 15:00 BST with the title of 'Navigating MedTech Regulation Pathways in Developed and Emerging Markets'. To find more information and to register click here.

Navigating MedTech Regulation Pathways in Developed and Emerging Markets2020-09-08T10:24:11+00:00


Getting the most out of antimicrobial surveillance
– by Mariana Castanheira

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Surveillance has been promoted as an important tool to monitor the prevalence of antimicrobial resistance. Beyond this purpose, surveillance is conducted to identify the increase in prevalence of certain pathogens,


Getting the most out of antimicrobial surveillance
– by Mariana Castanheira2021-01-25T08:29:27+00:00

CARB-X – How to Prepare for an FDA Pre-IND Meeting: Planning for Success

On 28th May 2020 at 17:00 CEST - 18:00 CEST, CARB-X will host a webinar on how to prepare for an FDA pre-IND meeting. Carmella Moody and Michael Bevilacqua will present on how best to prepare for these meetings to ensure maximum results. To find more information and to register click here.

CARB-X – How to Prepare for an FDA Pre-IND Meeting: Planning for Success2020-05-19T11:17:07+00:00

How to use the Global AMR R&D Hub’s Dynamic Dashboard

The Global AMR R&D Hub have announced their first set of webinars. These sessions will be held at two different times to suit various time zones on the 27th May 2020 at 2:00 - 3:00 pm GMT and the 28th May at 07:00 - 08:00 am GMT. The webinars will focus on providing a better understanding of their Dynamic Dashboard. For information on the speakers and to register, please visit the Global AMR R&D Hub website.

How to use the Global AMR R&D Hub’s Dynamic Dashboard2020-09-08T10:28:24+00:00


COVID-19 and antimicrobial resistance: Are there any unknowns that will become known?
– by Stephan Harbarth

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” COVID-19 represents an unprecedented public health crisis that will bring many novel insights. This worldwide disturbance will probably affect the epidemiology of antimicrobial resistance (AMR) in many different ways that


COVID-19 and antimicrobial resistance: Are there any unknowns that will become known?
– by Stephan Harbarth2021-01-25T08:29:39+00:00


COVID-19 and its impact on antimicrobial stewardship
– by Andrew Seaton

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial stewardship (AMS) is a system-wide approach to guiding, promoting and overseeing the safe and judicious use of antimicrobials. An AMS programme aims to safeguard antimicrobials, especially antibiotics, for future


COVID-19 and its impact on antimicrobial stewardship
– by Andrew Seaton2021-01-25T08:29:52+00:00

GARDP: Bringing new treatments for drug-resistant infections to all who need them

Speakers:  Seamus O' Brien, R&D Director, GARDP François Franceschi, Asset Evaluation and Development Project Leader, GARDP Sally Ellis, Neonatal Sepsis Project Leader, GARDP Moderator: Laura Piddock, Director of Scientific Affairs, GARDP This webinar provided an overview and update on GARDP's efforts to bring new antibiotic treatments for drug-resistant infections to all who need them. The following topics were presented: Antibiotic resistance and the GARDP response Tackling the growing threat of hospital infections Developing new treatments for neonatal sepsis The

GARDP: Bringing new treatments for drug-resistant infections to all who need them2020-10-09T11:13:19+00:00

Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations

Speaker: Vincent H. Tam, Professor, University of Houston College of Pharmacy (USA) Moderator: Shampa Das, Senior Lecturer, Centre of Excellence in Infectious Diseases Research, University of Liverpool (UK)  In this webinar, Vincent H. Tam presented his work on studying PK/PD in fixed dose beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations. Topics discussed included: Understanding the inherent challenges associated with PK/PD of BL/BLI combinations Demonstrating new approaches to gain useful insights from preclinical PK/PD models The presentation was followed by a Q&A session.

Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations2020-12-16T14:59:58+00:00


The critical need for alternative approaches to address antibiotic treatment failure
– by Bob Hancock

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The O’Neill report1 suggested that up to 10 million people will die from antibiotic resistant infections by 2050. This figure has been adopted by health authorities, researchers and the general


The critical need for alternative approaches to address antibiotic treatment failure
– by Bob Hancock2021-01-25T08:30:03+00:00


COVID-19: Pourquoi il est plus important que jamais de s’attaquer à la crise silencieuse des infections résistantes aux médicaments
– par Manica Balasegaram

Le spectre d’une maladie infectieuse prenant les proportions d’une pandémie et faisant des dizaines de milliers de victimes dans le monde n’est plus un scénario cauchemardesque théorique. La «maladie X» de l’Organisation mondiale de la Santé est là et, malgré les efforts constants déployés par l’OMS et d’autres pour maintenir cette menace au centre des préoccupations politiques, le monde a en grande partie été pris au dépourvu. S’il y a d’ores et déjà des leçons à tirer de la


COVID-19: Pourquoi il est plus important que jamais de s’attaquer à la crise silencieuse des infections résistantes aux médicaments
– par Manica Balasegaram2020-04-16T11:27:28+00:00

Probability of target attainment analyses for dose selection in antimicrobial drug development

Speaker: Shampa Das, Senior Lecturer, Centre of Excellence in Infectious Diseases Research, University of Liverpool (UK)  Moderator: Vincent H. Tam, Professor, University of Houston (US)  In this webinar, Shampa Das gave an overview of her work in studying the PK/PD and probability of target attainment for dose selection. Topics discussed included: An overview of what is meant by the probability of target attainment (PTA) How it is calculated and what data is used for this How PTA is used

Probability of target attainment analyses for dose selection in antimicrobial drug development2020-12-16T15:02:14+00:00


COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever
– by Manica Balasegaram

Artikel auf Deutsch lesen Lire en français PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The spectre of an infectious disease pandemic killing tens of thousands of people across the globe is no longer a


COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever
– by Manica Balasegaram2020-05-07T14:04:19+00:00

PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

Speaker: Alexander J. Lepak, Assistant Professor, University of Wisconsin School of Medicine and Public Health (US) Moderator: Peter Warn, Magic Bullet Consulting (UK) In this webinar, Alexander J. Lepak reviewed critical study elements that lead to robust preclinical PK/PD results in the murine model. Topics discussed included: Understanding and embracing the inherent variability in many components of the murine model Demonstrating how to generate and interpret preclinical murine model PK/PD results The presentation was followed by a Q&A session. *

PK/PD murine infection models: Focus on study elements, variability, and interpretation of results2020-12-16T15:04:02+00:00


Bringing antimicrobial research and development to Africa – the time is now
– by Greg Basarab and Kelly Chibale

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial resistance (AMR) has been an ongoing threat to public health in South Africa as well as other countries in Africa. Disturbingly, the burden in the continent from infectious diseases


Bringing antimicrobial research and development to Africa – the time is now
– by Greg Basarab and Kelly Chibale2021-01-25T08:31:32+00:00


Are new antibiotic combinations the solution to the AMR crisis?
– by Anthony Coates

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The traditional model for the development and marketing of new chemical entity (NCE) antibiotics has collapsed. The companies which develop NCEs for resistant bacteria struggle to survive in the market. NCE


Are new antibiotic combinations the solution to the AMR crisis?
– by Anthony Coates2021-01-25T08:32:02+00:00

Ramesh Agarwal

Ramesh Agarwal works as a Professor of Paediatrics, leads the Newborn Division and WHO-CC at the All India Institute of Medical Sciences, New Delhi, India. He is engaged in establishing a program on Neonatal Sepsis involving institutions and scientists of diverse background in India and beyond. The program so far has produced research outputs that have added meaningful value to our understanding. He has a keen interest in healthcare technology innovation and supports and mentors many groups that makes healthcare

Ramesh Agarwal2020-08-17T13:48:41+00:00

M. Javad Aman

Javad Aman has been the President and Chief Scientific Officer (CSO) of Integrated BioTherapeutics, Inc. (IBT), a US biotechnology company focused on the discovery of vaccines and immunotherapeutics for emerging infectious diseases. Since 2007, he has led a group of 40 people working on several programmes on the discovery and development of vaccines and antibody therapeutics for several multidrug-resistant bacteria, primarily S. aureus as well as several viral diseases. He has worked in the USA at the National Institutes

M. Javad Aman2021-05-25T16:43:02+00:00

Jeffrey Ambroso

Jeffrey L. Ambroso is a board-certified toxicologist with 21 years of experience in nonclinical safety evaluation of drugs and biotechnology products, in both public and private sectors. At RTI International, Jeffrey works closely with both the TB Alliance and CARB-X to develop novel therapies to treat bacterial pathogens. He has served as the preclinical safety representative on multiple project teams developing drugs for a variety of indications.

Jeffrey Ambroso2020-05-28T14:04:29+00:00

Antoine Andremont

Antoine Andremont is currently Emeritus Professor at the Paris Diderot University Medical School, France, a scientific advisor at the French Ministry of Higher Education, Research and Innovation, and serves as an expert witness for the French National Highest Judiciary Court (Cour de Cassation). He is also the co-founder and a senior scientific advisor at biotechnology company Da Volterra - which he created in 2000 to research and understand the impact of antibiotics on the intestinal flora microbiota, the development and

Antoine Andremont2020-02-04T10:06:36+00:00

John N. van den Anker

John van den Anker is a renowned paediatric consultant based at the Children’s National Medical Center Washington, DC, whose research has resulted in a much more evidence-based use of antibacterial agents such as aminoglycosides, cephalosporins, penicillins, meropenem, and vancomycin in children. John holds many titles including, the Evan and Cindy Jones Endowed Professor of Paediatric Clinical Pharmacology at Children’s National Medical Center; the Eckenstein-Geigy Distinguished Professor in Paediatric Pharmacology and Pharmacometrics at the University of Basel Children’s Hospital in Switzerland,

John N. van den Anker2020-02-04T10:07:09+00:00

Anand Anandkumar

Anand Anandkumar is co-founder and CEO of Bugworks, India. A startup working on tackling the problem of drug resistance. Bugworks is designing next-generation antibiotics that can tackle a broad spectrum of superbugs and will enter clinical trials in late 2020. More recently the company has also forayed into the design of broad-spectrum anti-virals. Bugworks has won many national and international innovation awards including the Best biotech startup in India 2015, Economic Times Top Innovator award 2017 and is the

Anand Anandkumar2021-06-02T07:27:38+00:00

Carl Balibar

Carl Balibar is a Principal Scientist in the department of Infectious Disease and Vaccines at Merck & Co. which he joined in 2012. He is an expert in antibiotic mechanism of action and antibacterial drug discovery. He is specifically responsible for efforts ranging from early discovery and target validation through clinical development utilizing various modalities in support of anti-infective drug discovery. Carl has written more than 30 papers and book chapters and participated in the discovery and development of the

Carl Balibar2020-05-28T13:57:30+00:00

Peter Beyer

Peter Beyer is a trained lawyer and Senior Advisor at the World Health Organization (WHO) where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was involved in establishing the Global Antibiotic R&D Partnership (GARDP) as a WHO and DNDi joint initiative as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade

Peter Beyer2020-05-28T13:56:06+00:00

Jessica Blair

Jessica Blair currently holds a Biotechnology and Biological Sciences Research Council (BBSRC) David Phillips Fellowship and is a lecturer in Antimicrobial Resistance at the Institute of Microbiology and Infection at the University of Birmingham UK. She is an expert in the molecular mechanisms of antibiotic resistance and specifically bacterial efflux pumps. Her team at the University of Birmingham are predominantly interested in how efflux contributes to antibiotic resistance and how the expression of efflux pumps are regulated as well as

Jessica Blair2020-08-18T14:41:44+00:00

Patricia A. Bradford

Patricia A. Bradford is the owner of Antimicrobial Development Specialists LLC, a consulting company that focuses on the late-stage development of antibiotics. She has previously been responsible for microbiology support at AstraZeneca, where she contributed to the successful development and approval of ceftazidime-avibactam. Before joining AstraZeneca, Patricia worked in antibiotic research for Novartis, Wyeth Pharmaceuticals and Lederle Laboratories. At Wyeth Pharmaceuticals, she worked on several antibiotic projects and was instrumental in the team that wrote the dossier for the registration

Patricia A. Bradford2021-04-21T12:59:33+00:00

Mark Brönstrup

Mark Brönstrup has been head of the Department of Chemical Biology at the Helmholtz Centre for Infection Research and since 2013 he has also held a Professorship at the Leibniz Universität Hannover. After his graduation, he worked as a laboratory head for Mass Spectrometry at Aventis. This was complemented by a research sabbatical in 2003 at Harvard Medical School. He then led the Natural Product Sciences section at Sanofi-Aventis in Frankfurt with the goal of discovering leads from natural sources

Mark Brönstrup2020-08-13T16:09:57+00:00

John J.S. Cadwell

John J.S. Cadwell is president and CEO of FiberCell Systems Inc, a company he founded in the year 2000 which specializes in the development and supply of laboratory-scale 3-D capillary hollow fibre bioreactors. FiberCell Systems Inc. is a primary supplier of hollow fibre modules for use in the hollow fibre infection model (HFIM) which was developed to precisely mimic human in vivo bioavailability of antibiotic, anti-cancer and anti-viral drugs in a closed, bio-safe, reproducible system. He has worked directly

John J.S. Cadwell2021-05-25T16:45:08+00:00

Marco Cavaleri

Marco Cavaleri is the head of the office of biological health threats and vaccines strategy at the European Medicines Agency (EMA). He is the Chair of the EMA COVID-19 Taskforce and responsible for EMA activities for emergent pathogens, vaccines and AMR. Marco is a pharmacologist who has spent several years in the industry within research and development mainly in the area of anti-infectives covering different positions in preclinical and clinical development. In 2005 he joined the EMA as scientific administrator

Marco Cavaleri2021-02-05T08:47:05+00:00

James Collins

James (Jim) Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT), as well as a member of the Harvard-MIT Health Sciences & Technology Faculty. He is a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT and Harvard. Being one of the founders of the field of synthetic biology, his research

James Collins2020-05-28T13:55:18+00:00

Lloyd Czaplewski

Lloyd Czaplewski is Chief Scientific Officer for Persica Pharmaceuticals Limited and a Director of Chemical Biology Ventures where he provides life and chemical sciences consultancy services. Previously, Lloyd has served as an R&D executive for Biota, Prolysis, and British Biotech Pharmaceuticals. In his scientific career so far, he has led the creation and clinical evaluation of an engineered cytokine, discovery of the potential for minimal lentiviral vectors in antigen presentation, and demonstrating ability to create and lead structure-informed screening. He

Lloyd Czaplewski2020-05-28T13:54:16+00:00

Shampa Das

Shampa Das is a Senior Lecturer at the University of Liverpool and a Pharmacokinetics and Pharmacodynamics (PK/PD) consultant. Following 17 years within the pharmaceutical industry, Shampa has extensive expertise in using PK/PD for developing Clinical Pharmacology and dose strategies to support the clinical development and regulatory approval of new anti-infective drugs. Shampa is a senior leader within the Antimicrobial Pharmacodynamics and Therapeutics group which supports biotechnological and pharmaceutical companies to develop new antimicrobial agents by developing the critical Pharmacokinetics and

Shampa Das2020-08-13T16:34:18+00:00

David Denning

David Denning is an infectious diseases clinician with expertise in fungal diseases. He has been a Professor of Infectious Diseases and Global Health at the University of Manchester since 2005. From 2009 to 2020, David led the National Aspergillosis Centre, Manchester, a referral centre in the UK for all patients with chronic pulmonary aspergillosis. His current academic interests are chronic and allergic pulmonary fungal disease, the global burden of fungal infection, resistance in Aspergillus and getting new antifungals developed. He

David Denning2020-06-04T07:09:07+00:00

Harpal Dhillon

Harpal Dhillon is a pharmacist, founder of AntiBx and a Global Medical Value consultant. Harpal has amassed over 15 years of experience working across healthcare, public health, academia and the pharmaceutical industry in a variety of roles within infectious diseases. He has specialized in developing innovative strategies and initiatives to optimize antibiotic prescribing. This has included the launch of TARGET antibiotics in the UK and the execution of an EU-wide compassionate use programme for an antibiotic. His experience led to

Harpal Dhillon2020-06-22T14:46:30+00:00

Thomas Dougherty

Thomas Dougherty is a Senior Scientist in the laboratory in Professor Steve Lory in the Department of Microbiology at Harvard Medical School. Here, he researches compounds that inhibit the lipoprotein pathway in the periplasm, to pharmacologically compromise the outer membrane integrity of Gram-negative bacteria. Thomas spent 8 years at the Rockefeller University in Alexander Tomasz’s laboratory, 3 as a postdoctoral fellow and 5 as an assistant professor. He worked on studies funded by the United States, National Institute of Health

Thomas Dougherty2020-08-17T14:14:23+00:00

Christopher Dowson

Christopher Dowson is a professor of microbiology at Warwick University, UK and a Director of Antimicrobial Discovery Solutions Ltd. His research interests encompass evolution, epidemiology and mechanisms of antibiotic resistance, much of which underpins academic, industrial open-source and for-profit, multitargeting antibiotic discovery programmes. A particular focus has been to better understand how penicillin targets bacteria. Christopher has led several multinational research consortia and helped establish a multidisciplinary doctoral training programme to tackle drug-resistant infections (Medical Research Foundation, UK). Christopher

Christopher Dowson2021-05-25T16:30:25+00:00

Richard H. Ebright

Richard H. Ebright is Board of Governors Professor of Chemistry and Chemical Biology at Rutgers University, USA and Laboratory Director at the Waksman Institute of Microbiology, also in the USA. His research focuses on the structure, mechanism, and regulation of bacterial transcription complexes, as well as on the development of inhibitors of bacterial transcription and broad-spectrum antibacterial agents and agents against tuberculosis. His research employs tools of structural biology, single-molecule biophysics, molecular biology, and drug discovery. He has received

Richard H. Ebright2021-05-25T16:45:56+00:00

Roger M. Echols

Roger Echols is Principal of Infectious Diseases at Drug Development Consulting, LLC, a consulting firm established in 2008 focused on the development of anti-microbial therapies including drugs, biologics and devices. Roger is a physician trained in infectious diseases who has extensive experience in the development of anti-bacterial, anti-viral and antifungal drugs both in the USA and internationally. His career in the pharmaceutical industry started in 1989 as Medical Director at Bayer leading the USA development of ciprofloxacin. Before this,

Roger M. Echols2021-05-26T16:12:58+00:00

Flavio Emery

Flavio Emery is Professor of Medicinal Chemistry and Heterocyclic Chemistry at the School of Pharmaceutical Sciences at Ribeirao Preto at University of São Paulo (FCFRP/USP), Brazil, since 2008. His research is focused on developing new antimicrobial candidates, trying to advance the chemical space of antiparasitic and antibacterial compounds, both from natural or synthetic products. Since 2012, his research has focused on exploring molecular targets for designing new therapeutic candidates for tuberculosis, Chagas disease, leishmaniasis and schistosomiasis using natural products

Flavio Emery2021-05-25T16:30:08+00:00

Cecilia Ferreyra

Cecilia joined the Foundation for Innovative New Diagnostics (FIND) as AMR Medical Officer in 2018. Here, she supports projects addressing gaps in the availability and use of diagnostic tests for antimicrobial resistance in order to better guide the appropriate use of treatments. Prior to joining FIND, Cecilia worked at Médecins Sans Frontières (MSF) for 14 years in several countries such as China, Somalia, South Sudan and Uganda. In this role, she implemented HIV and tuberculosis (TB) activities in conflict affected

Cecilia Ferreyra2020-05-28T13:50:21+00:00

Lena Friberg

Lena Friberg is Professor of Pharmacometrics at the Faculty of Pharmacy at Uppsala University, Sweden, a position she has held since 2014. Lena obtained her PhD degree in Pharmacokinetics and Drug Therapy in 2003 and spent nearly two years as a postdoctoral fellow at the University of Queensland in Australia. She has published over 125 original articles and nearly 15 reviews and book chapters in the area and has an H-index over 40. Her research is focused on advancing pharmacometric

Lena Friberg2020-06-04T08:29:48+00:00

César de la Fuente

César de la Fuente is a Presidential Assistant Professor at the University of Pennsylvania, where he leads the Machine Biology group to integrate synthetic biology, microbiology and artificial intelligence. His group aims to develop computer-made tools and medicines to replenish our current antibiotic arsenal. César is a National Institutes of Health (NIH) Maximizing Investigator's Research Award investigator, a BBRF Young Investigator, and has received recognition and research funding from numerous other groups. César was also recognized by MIT Technology

César de la Fuente2021-05-25T16:29:59+00:00

REVIVE

REVIVE is a space for everybody with an interest in antimicrobial R&D.

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. We were created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We aim to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children.

CONNECT